{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["138(24)"],"submitter":["Rejeski K"],"pubmed_abstract":["Hematotoxicity represents a frequent chimeric antigen receptor (CAR) T-cell-related adverse event and remains poorly understood. In this multicenter analysis, we studied patterns of hematopoietic reconstitution and evaluated potential predictive markers in 258 patients receiving axicabtagene ciloleucel (axi-cel) or tisagenlecleucel (tisa-cel) for relapsed/refractory large B-cell lymphoma. We observed profound (absolute neutrophil count [ANC] <100 cells per µL) neutropenia in 72% of patients and prolonged (21 days or longer) neutropenia in 64% of patients. The median duration of severe neutropenia (ANC < 500 cells per µL) was 9 days. We aimed to identify predictive biomarkers of hematotoxicity using the duration of severe neutropenia until day +60 as the primary end point. In the training c"],"journal":["Blood"],"pagination":["2499-2513"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8893508"],"repository":["biostudies-literature"],"pubmed_title":["CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma."],"pmcid":["PMC8893508"],"pubmed_authors":["Frolich L","Locke FL","Schmidt C","Weigert O","Mougiakakos D","Perez A","Bethge W","Faul C","Mackensen A","Rejeski K","Ayuk F","Bachy E","Fehse B","Sesques P","Blumenberg V","Salles G","Subklewe M","Jentzsch L","Jallades L","Hoster E","Berger C","Ackermann J","Karschnia P","Dreyling M","von Bergwelt-Baildon M","Jain MD","Bucklein V"],"additional_accession":[]},"is_claimable":false,"name":"CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma.","description":"Hematotoxicity represents a frequent chimeric antigen receptor (CAR) T-cell-related adverse event and remains poorly understood. In this multicenter analysis, we studied patterns of hematopoietic reconstitution and evaluated potential predictive markers in 258 patients receiving axicabtagene ciloleucel (axi-cel) or tisagenlecleucel (tisa-cel) for relapsed/refractory large B-cell lymphoma. We observed profound (absolute neutrophil count [ANC] <100 cells per µL) neutropenia in 72% of patients and prolonged (21 days or longer) neutropenia in 64% of patients. The median duration of severe neutropenia (ANC < 500 cells per µL) was 9 days. We aimed to identify predictive biomarkers of hematotoxicity using the duration of severe neutropenia until day +60 as the primary end point. In the training c","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Dec","modification":"2026-06-07T03:22:46.606Z","creation":"2025-04-19T13:19:57.264Z"},"accession":"S-EPMC8893508","cross_references":{"pubmed":["34166502"],"doi":["10.1182/blood.2020010543"]}}